REGULATORY

Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme

July 24, 2019
The Drug Pricing Organization’s (DPO) proposal last month to set lower launch premium rates for high-priced cell and gene therapies is “unacceptable,” the Forum for Innovative Regenerative Medicine (FIRM) said on July 24. As part of its broader proposal towards…

To read the full story

Related Article

REGULATORY

By Philip Carrigan

Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…

By Yoshinori Sagehashi

Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…

Members of a health ministry panel on pharmaceutical regulations on February 8 broadly agreed on a proposal to allow regulatory…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…